查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1448557

全球重组蛋白治疗 CDMO 市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Recombinant Protein Therapeutics CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 280 Pages | 商品交期: 最快1-2个工作天内

价格

全球重组蛋白治疗 CDMO 市场需求预计将从 2023 年的 212.3 亿美元增至 2032 年的近 693.7 亿美元，2024-2032 年研究期间CAGR为 14.06%。

重组蛋白疗法 CDMO（合约开发和製造组织）涉及透过基因工程提供治疗性蛋白质开发和生产服务的公司。这些组织在推动生物製药、确保重组蛋白药物生产流程高效且合规方面发挥重要作用。

市场动态

重组蛋白疗法 CDMO 市场受到慢性病盛行率日益上升等因素的影响，推动了对生物製药解决方案的需求。由于专业服务提供者提供的成本效益和专业知识，将製造流程外包给合约开发和製造组织 (CDMO) 越来越受欢迎。生物技术的进步，包括基因治疗和个人化医疗，有助于市场的扩张。此外，重组蛋白製造的复杂性和对专业设施的需求促使生物製药公司寻求外部 CDMO 专业知识。对生物製药开发的监管支持和不断增长的重组蛋白药物管道进一步推动了市场的成长，为 CDMO 提供者创造了机会，以满足生物製药行业不断变化的需求。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球重组蛋白治疗 cdmo 市场的每个细分市场进行了包容性评估。重组蛋白治疗 cdmo 产业的成长和趋势为本研究提供了整体方法。

市场区隔

重组蛋白治疗 cdmo 市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人口统计数据以及即将到来的机会。

按类型

  • 生长激素
  • 干扰素
  • 疫苗
  • 免疫刺激剂
  • 其他的

按来源

  • 哺乳动物系统
  • 微生物系统
  • 其他的

按指示

  • 肿瘤学
  • 传染性疾病
  • 免疫系统疾病
  • 代谢紊乱
  • 血液系统疾病
  • 其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲重组蛋白治疗 CDMO 市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。重组蛋白治疗 CDMO 市场的主要参与者包括 Richter-Helm BioLogics、Lonza、Catalent, Inc、FUJIFILM Diosynth Biotechnologies、WuXi Biologics、Curia Global, Inc.、Batavia Biosciences BV、HALIX BV、BIOVIAN、Enzene Biosciences Ltd。包括对竞争竞争格局的整体看法，包括各种策略发展，例如关键併购、未来能力、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法论
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：重组蛋白治疗 CDMO - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按类型分類的市场吸引力分析
    • 按来源分類的市场吸引力分析
    • 按指标进行的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球重组蛋白治疗 CDMO 市场分析：按类型

  • 按类型概述
  • 历史和预测数据
  • 按类型分析
  • 生长激素
  • 干扰素
  • 疫苗
  • 免疫刺激剂
  • 其他的

第 6 章：全球重组蛋白治疗 CDMO 市场分析：依来源分类

  • 按来源概述
  • 历史和预测数据
  • 按来源分析
  • 哺乳动物系统
  • 微生物系统
  • 其他的

第 7 章：全球重组蛋白治疗 CDMO 市场分析：依适应症分类

  • 按适应症概述
  • 历史和预测数据
  • 按指标分析
  • 肿瘤学
  • 传染性疾病
  • 免疫系统疾病
  • 代谢紊乱
  • 血液系统疾病
  • 其他的

第 8 章：全球重组蛋白治疗 CDMO 市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区国家/地区销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 9 章：重组蛋白治疗 CDMO 公司的竞争格局

  • 重组蛋白治疗Cdmo市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 10 章：公司简介

  • 公司股份分析
  • 市场集中度
  • Richter-Helm BioLogics
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Lonza
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Catalent Inc
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • FUJIFILM Diosynth Biotechnologies
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • WuXi Biologics
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Curia Global Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Batavia Biosciences BV
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • HALIX BV
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • BIOVIAN
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Enzene Biosciences Ltd
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

Product Code: VMR112113789

The global demand for Recombinant Protein Therapeutics CDMO Market is presumed to reach the market size of nearly USD 69.37 BN by 2032 from USD 21.23 BN in 2023 with a CAGR of 14.06% under the study period 2024 - 2032.

Recombinant protein therapeutics CDMO (Contract Development and Manufacturing Organization) involves companies providing services for the development and production of therapeutic proteins through genetic engineering. These organizations are important in advancing biopharmaceuticals, ensuring efficient and compliant production processes for recombinant protein-based drugs.

MARKET DYNAMICS

The recombinant protein therapeutics CDMO market is influenced by factors such as the increasing prevalence of chronic diseases, driving the demand for biopharmaceutical solutions. Outsourcing of manufacturing processes to Contract Development and Manufacturing Organizations (CDMOs) is gaining traction due to cost-effectiveness and expertise offered by specialized service providers. Advancements in biotechnology, including gene therapy and personalized medicine, contribute to the market's expansion. Additionally, the complexity of manufacturing recombinant proteins and the need for specialized facilities drive biopharmaceutical companies to seek external CDMO expertise. Regulatory support for biopharmaceutical development and the growing pipeline of recombinant protein drugs further fuel the market's growth, creating opportunities for CDMO providers to cater to the evolving needs of the biopharmaceutical industry.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of recombinant protein therapeutics cdmo. The growth and trends of recombinant protein therapeutics cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the recombinant protein therapeutics cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

  • Growth Hormones
  • Interferons
  • Vaccines
  • Immunostimulating Agents
  • Others

By Source

  • Mammalian Systems
  • Microbial Systems
  • Others

By Indication

  • Oncology
  • Infectious Diseases
  • Immunological Disorders
  • Metabolic Disorders
  • Haematological Disorders
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Recombinant Protein Therapeutics CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Recombinant Protein Therapeutics CDMO market include Richter-Helm BioLogics, Lonza, Catalent, Inc, FUJIFILM Diosynth Biotechnologies, WuXi Biologics, Curia Global, Inc., Batavia Biosciences B.V., HALIX B.V., BIOVIAN, Enzene Biosciences Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . RECOMBINANT PROTEIN THERAPEUTICS CDMO - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Type
    • 3.7.2 Market Attractiveness Analysis By Source
    • 3.7.3 Market Attractiveness Analysis By Indication
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET ANALYSIS BY TYPE

  • 5.1 Overview by Type
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Type
  • 5.4 Growth Hormones Historic and Forecast Sales by Regions
  • 5.5 Interferons Historic and Forecast Sales by Regions
  • 5.6 Vaccines Historic and Forecast Sales by Regions
  • 5.7 Immunostimulating Agents Historic and Forecast Sales by Regions
  • 5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET ANALYSIS BY SOURCE

  • 6.1 Overview by Source
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Source
  • 6.4 Mammalian Systems Historic and Forecast Sales by Regions
  • 6.5 Microbial Systems Historic and Forecast Sales by Regions
  • 6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET ANALYSIS BY INDICATION

  • 7.1 Overview by Indication
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Indication
  • 7.4 Oncology Historic and Forecast Sales by Regions
  • 7.5 Infectious Diseases Historic and Forecast Sales by Regions
  • 7.6 Immunological Disorders Historic and Forecast Sales by Regions
  • 7.7 Metabolic Disorders Historic and Forecast Sales by Regions
  • 7.8 Haematological Disorders Historic and Forecast Sales by Regions
  • 7.9 Others Historic and Forecast Sales by Regions

8 . GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE RECOMBINANT PROTEIN THERAPEUTICS CDMO COMPANIES

  • 9.1. Recombinant Protein Therapeutics Cdmo Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF RECOMBINANT PROTEIN THERAPEUTICS CDMO INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Richter-Helm BioLogics
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. Lonza
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Catalent Inc
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. FUJIFILM Diosynth Biotechnologies
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. WuXi Biologics
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Curia Global Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. Batavia Biosciences B.V.
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. HALIX B.V.
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. BIOVIAN
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Enzene Biosciences Ltd
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Type (USD MN)
  • Growth Hormones Market Sales by Geography (USD MN)
  • Interferons Market Sales by Geography (USD MN)
  • Vaccines Market Sales by Geography (USD MN)
  • Immunostimulating Agents Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by Source (USD MN)
  • Mammalian Systems Market Sales by Geography (USD MN)
  • Microbial Systems Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis by Indication (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Infectious Diseases Market Sales by Geography (USD MN)
  • Immunological Disorders Market Sales by Geography (USD MN)
  • Metabolic Disorders Market Sales by Geography (USD MN)
  • Haematological Disorders Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Recombinant Protein Therapeutics Cdmo Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Recombinant Protein Therapeutics Cdmo Report
  • Market Research Process
  • Market Research Methodology
  • Global Recombinant Protein Therapeutics Cdmo Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Type
  • Market Attractiveness Analysis by Source
  • Market Attractiveness Analysis by Indication
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Type (USD MN)
  • Growth Hormones Market Sales by Geography (USD MN)
  • Interferons Market Sales by Geography (USD MN)
  • Vaccines Market Sales by Geography (USD MN)
  • Immunostimulating Agents Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Source (USD MN)
  • Mammalian Systems Market Sales by Geography (USD MN)
  • Microbial Systems Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Indication (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Infectious Diseases Market Sales by Geography (USD MN)
  • Immunological Disorders Market Sales by Geography (USD MN)
  • Metabolic Disorders Market Sales by Geography (USD MN)
  • Haematological Disorders Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.